Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955486 | 0.88 | GPR119 (0.40) | ALDH1A1 | |
| SCHEMBL3953695 | 0.82 | KDM4E (0.36) | ALDH1A1SLC6A9 | |
| SCHEMBL3956292 | 0.82 | MAPT (0.47) | HSD17B10ALOX15ALDH1A1 | |
| SCHEMBL27655973 | 0.82 | CHRM1 (0.40) | CHRM3CHRM1HSD17B10ALDH1A1TP53 | |
| SCHEMBL3957138 | 0.81 | BACE1 (0.39) | ALDH1A1 | |
| SCHEMBL3960632 | 0.79 | MTOR (0.41) | ALDH1A1 | |
| SCHEMBL27662339 | 0.79 | GRM5 (0.35) | CHRM3CHRM1ALDH1A1TP53 | |
| SCHEMBL4493007 | 0.78 | SLC6A2 (0.55) | — | |
| Hydrochloric Acid SCHEMBL3961907 | 0.78 | SLC6A2 (0.56) | — | |
| SCHEMBL3950407 | 0.77 | STS (0.45) | ALDH1A1TP53NPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-7419980-B2 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7402698-B2 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| CN-1897950-A | Fused aryl and heteroaryl derivatives and methods of use thereof | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037283-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | CHRM3 427/4885CHRM1 1585/4885HSD17B10 280/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | CHRM3 481/4885CHRM1 2069/4885HSD17B10 1356/4885 |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | HTR3A, MAOA, GLS | CHRM3 278/4885CHRM1 1147/4885HSD17B10 339/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | CHRM3 194/4885CHRM1 659/4885HSD17B10 464/4885 |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | MAOA, MAOB, SDHA | CHRM3 1108/4885CHRM1 1332/4885HSD17B10 671/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | CHRM3 1108/4885CHRM1 1332/4885HSD17B10 671/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | CHRM3 853/4885CHRM1 1911/4885HSD17B10 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.